Reply Shapes the Future of Autonomous Mobile Robots with the Power of Microsoft Azure
6.7.2021 10:30:00 EEST | Business Wire | Press release
Reply announced today that it has developed an end-to-end solution architecture for autonomous mobile robots (AMR) on Microsoft Azure that enables new business applications across industries, reduces upfront costs and allows for the rapid implementation of customer-specific robotics use cases.
The solution combines Microsoft Azure services, the agility of Boston Dynamics' SPOT and Reply’s knowledge of intelligent cloud computing services, edge computing and artificial intelligence. To demonstrate the capabilities of a scalable and versatile robotics platform, Reply implemented an automated vehicle-damage-detection solution for rental or leasing companies that leverages this architecture. In fact, rental or leasing companies must inspect vehicles for any damage after they are returned in order to ensure the safety and quality of their fleet for their customers. This is usually done in the time- and cost-consuming manual process of walking around the car, visually inspecting it, assessing the severity of the damage and conducting a damage report.
Reply integrates Azure Cognitive Services, Machine Learning and DevOps as well as Power Apps and Power BI. Thanks to Azure's intelligent service foundation, agile workflows and machine learning, this process can be fully automated. Using computer vision, SPOT moves freely through the parking area and scans the license plates to find the right vehicle. Once detected, it walks around the vehicle to record its condition by continuously collecting visual data with its camera and sensors. This information is processed “on the edge” or transmitted to the cloud, where advanced image recognition and machine leaning algorithms perform the damage detection. All detected damages are saved in the return protocol, and they can be presented to the customer and the fleet manager for approval.
“This platform sets the power of Microsoft Azure on the move by bringing it from the Cloud to the Edge and into highly advanced mobile robotic devices, giving them the autonomy to unlock novel business use cases. Thanks to the agile reference architecture, we are able to implement customer-specific use cases in various industries that include all types of mobile robots or drones”, comments Filippo Rizzante, CTO Reply.
“Reply is a long-term, trusted partner in delivering Azure IoT solutions, and we’re delighted to continue our collaboration on this new scalable robotics offering. By leveraging Microsoft Azure, we can help accelerate this transformation by making it easier for businesses to bring AI and analytics capabilities to these autonomous systems in a consistent and secure way,” adds Lakecia Gunter, Vice President and GM, Global IOT Channel at Microsoft.
With their agility, autonomous mobile robots (AMR) are able to move independently from a central infrastructure on terrain that is not traditionally designed for robots. They can be used in hazardous environments and environments, that are harmful to people. According to ResearchAndMarkets.com, the global market for automated guided vehicle (AGV) and AMR is expected to reach $13.2 Billion by 2026 with a growth rate of around 35%. Both AGVs and AMRs collectively are going to cross the installed base of 1.5 Million in the next 5 years to make mobile robots a new normal in our day-to-day operational activities.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Source Global Mobile Robots (AGV & AMR) Market:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005133/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Sandra Dennhardt
s.dennhardt@reply.com
+49 170 454 62 29
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom